Parameswaran Hari, MD, MRCP

Chief, Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

Hindi, Urdu, Tamil, Malayalam, English

Cancer Center - Froedtert Hospital

(414) 805-6800

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine
MRCP (U.K.) - Member Royal College of Physicians

Biography

Parameswaran Hari, MD, MRCP, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief in the Division of Hematology and Oncology in the Department of Medicine. After medical school in India, he completed training in Internal Medicine and Hematology in the United Kingdom and then in Medical Oncology and Transplantation at the Medical College of Wisconsin.

Research Interests

His primary clinical interests are in cellular therapies and plasma cell disorders - multiple Myeloma, Amyloidosis and other monoclonal gammopathies. Dr. Hari is also Scientific Director of the plasma cell disorders working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.

(Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF.) Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):526-535 PMID: 33985931 SCOPUS ID: 2-s2.0-85105544057 05/15/2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

(Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S.) Lancet. 2021 07 24;398(10297):314-324 PMID: 34175021 SCOPUS ID: 2-s2.0-85111003312 06/28/2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.

(Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A.) Leukemia. 2021 Jul;35(7):2141 PMID: 34091601 SCOPUS ID: 2-s2.0-85107532822 06/07/2021
Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift.

(Mohan M, Hari P, Dhakal B.) JCO Oncol Pract. 2021 07;17(7):405-413 PMID: 34003675 SCOPUS ID: 2-s2.0-85111055909 05/19/2021
Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation.

(Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A.) Leuk Res. 2021 Jun 23;109:106648 PMID: 34182226 SCOPUS ID: 2-s2.0-85109506946 06/29/2021
Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

(Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M.) Clin Lymphoma Myeloma Leuk. 2021 Jun 18 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021
SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopenia.

(Zhu W, Zheng Y, Yu M, Wei J, Zhang Y, Topchyan P, Nguyen C, Janecke R, Kreuziger LB, White GC, Hari P, Aster R, Cui W, Jobe S, Graham MB, Wang D, Wen R.) Res Sq. 2021 Apr 26 PMID: 34013243 PMCID: PMC8132233 05/21/2021
PD-1 blockade after bispecific LV20.19 CAR-T modulates CAR T-cell immunophenotype without meaningful clinical response.

(Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN.) Haematologica. 2021 Apr 15 PMID: 33853295 04/16/2021
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.

(Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A.) Transplant Cell Ther. 2021 03;27(3):264.e1-264.e7 PMID: 33781533 PMCID: PMC8010222 SCOPUS ID: 2-s2.0-85101183550 03/31/2021
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

(Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S.) Front Immunol. 2021;12:667054 PMID: 34149703 PMCID: PMC8206561 SCOPUS ID: 2-s2.0-85108140164 06/22/2021
Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation.

(Thapa B, Ahmed G, Mohan M, Shponka V, Hari P.) Case Rep Hematol. 2021;2021:5590975 PMID: 33884207 PMCID: PMC8041536 04/23/2021